8,588 Shares in AbbVie Inc. $ABBV Bought by OceanIQ Capital LLC

OceanIQ Capital LLC bought a new position in AbbVie Inc. (NYSE:ABBV) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 8,588 shares of the company’s stock, valued at approximately $2,148,000. AbbVie accounts for approximately 1.3% of OceanIQ Capital LLC’s holdings, making the stock its 14th largest position.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Norges Bank bought a new position in shares of AbbVie during the fourth quarter worth about $5,865,055,000. Corient Private Wealth LP acquired a new position in AbbVie during the 2nd quarter valued at about $559,736,000. Legal & General Group Plc acquired a new position in AbbVie during the 2nd quarter valued at about $2,905,952,000. Wellington Management Group LLP grew its position in AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after purchasing an additional 8,646,424 shares during the last quarter. Finally, Capital World Investors grew its position in AbbVie by 106.3% in the 4th quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock worth $2,986,777,000 after purchasing an additional 6,736,161 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 0.06% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

ABBV has been the topic of a number of recent analyst reports. Canaccord Genuity Group lifted their price target on AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a report on Monday, August 3rd. BMO Capital Markets increased their price objective on AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Guggenheim raised their target price on AbbVie from $261.00 to $288.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. BNP Paribas Exane boosted their price target on AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 11th. Finally, Bank of America reissued a “buy” rating on shares of AbbVie in a research note on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $276.64.

AbbVie Stock Up 1.6%

ABBV opened at $255.00 on Friday. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $267.47. The firm has a market cap of $450.52 billion, a PE ratio of 72.03, a P/E/G ratio of 1.13 and a beta of 0.29. The business has a fifty day simple moving average of $254.54 and a 200-day simple moving average of $230.76.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts anticipate that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were issued a $1.73 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. AbbVie’s dividend payout ratio is presently 195.48%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Qulipta migraine expansion: AbbVie reported positive Phase 3 LUNA results for atogepant (Qulipta) in preventing menstrual migraine. The treatment met its primary and secondary endpoints, potentially opening a new indication and supporting intermittent use rather than continuous daily dosing. This could expand Qulipta’s commercial opportunity and reinforce AbbVie’s position in migraine care. AbbVie’s migraine treatment meets late-stage study goal
• Positive Sentiment: Higher HSBC valuation: HSBC raised its price target for AbbVie to $315 from $300 while maintaining a Buy rating, signaling continued confidence in the company’s growth outlook and product pipeline. HSBC adjusts price target on AbbVie
• Positive Sentiment: Dividend maintained: AbbVie declared a quarterly cash dividend of $1.73 per share, payable Nov. 16 to shareholders of record Oct. 15. The unchanged payout supports the stock’s income appeal and reflects continued shareholder-return capacity. AbbVie declares quarterly dividend
• Neutral Sentiment: Pipeline and portfolio developments: Coverage highlighted the growth of Skyrizi and Rinvoq, the planned $10.9 billion Apogee Therapeutics acquisition, an ADARx collaboration and updated real-world data from an eye-implant study. These initiatives may diversify future growth, but their financial impact remains dependent on execution, approvals and clinical outcomes.
• Negative Sentiment: Regulatory setback: The FDA issued a Complete Response Letter for trenibotE, AbbVie’s fast-acting neurotoxin candidate. The action may delay the product’s launch and add uncertainty around the aesthetics pipeline. FDA issues Complete Response Letter for AbbVie’s trenibotE
• Negative Sentiment: Concentration and valuation concerns: Analysts continue to monitor AbbVie’s reliance on Skyrizi and the long-term effects of Humira’s patent-related decline. With the stock trading at a relatively elevated earnings multiple, execution risks and slower-than-expected diversification could limit further upside.

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.